Richardson Electronics (RELL) as of February 28, 2026 presents a balance sheet that is positive under the liquidation lens — a relatively unusual outcome for a going concern of this scale, driven primarily by the absence of long-term financial debt and a concentrated, largely tangible asset base. MFFAIS reports an operating liquidation value (OLV) of approximately $125.7 million, a liquid liquidation value (LLV) of $18.1 million, and a cash liquidation value (CLV) of negative $9.0 million against reported stockholders' equity of $160.2 million. Total assets are $199.8 million; total liabilities are $39.6 million, of which $37.8 million are current. The liability stack carries no outstanding bank debt (the $20M PNC revolving credit facility has zero drawings as of period end), which is the single most important structural positive for liquidation recovery. The asset side is dominated by inventory ($107.6M gross, net of a $7.8M reserve) and cash ($29.5M). Applying standard liquidation haircuts: cash at 100% yields $29.5M; AR at 92% on $27.0M yields $24.9M; inventory at 60% on $107.6M yields $64.6M; PP&E at 60% on $18.9M yields $11.3M; intangibles at 0% on $0.3M yields zero; deferred tax assets at 0% yield zero; ROU assets at 0% yield zero. Gross haircutted asset pool approximates $130M. Against face-value liabilities of $39.6M (including $1.6M operating lease liability), estimated equity recovery is roughly $90M. This is comfortably positive and well above the CLV/LLV metrics, indicating the balance sheet is not impaired in liquidation terms — the drag comes from the inventory haircut on a large, specialized inventory base. Key change since prior filing (Q2 FY26, period end November 29, 2025): cash declined from $33.1M to $29.5M as operations used $1.4M and investing consumed $3.4M in capex, partially offset by FX. Inventory rose from approximately $102.8M (May 31, 2025 year-end) to $107.6M, increasing the 60%-haircut drag by roughly $2.9M in liquidation terms. No new debt was incurred. The IMES/Healthcare asset disposal (Q3 FY25) is now fully in the rearview; the remaining exposure is a production commitment to DirectMed for ALTA CT tubes (12-18 months, not separately XBRL-tagged as a contingent liability) and a $1.2M deferred revenue obligation also now substantially recognized. The filing does not separately tag the ALTA CT supply agreement production commitment as a liability in XBRL; it is described in MD&A and Note 10 as an ongoing obligation. Filing discusses the ALTA CT X-ray tube manufacturing commitment in MD&A and Note 10 but does not separately tag the associated unfunded production obligation in XBRL.
▼ Community Notes